Prime Global, the international medical communications and market access group, today announced the launch of a new technical and strategic communications consultancy, Prime Omics. Prime Omics will support the decoding of molecular landscapes for precise communications and healthcare access, working alongside the rest of the Prime Global group.
Omic-based technologies such as next-generation sequencing and gene expression profiling are rapidly evolving and becoming an integral part of drug discovery, patient diagnosis, patient management, and disease treatment. Prime Omics provides expert guidance on how to decode and characterise data from biological molecules such as DNA, RNA, and proteins, as well as metabolic pathways and microbes, and how to communicate that information to help improve patient outcomes.
Valerie Moss, Group Managing Director at Prime Global, says, “Prime Omics has developed organically from scientific expertise within Prime Global. I am proud that our team has a proven track record in interpreting omic data accurately and reliably and translating that information for a range of audiences from bench to bedside, including HCPs, pharma, payers and patients.”
Prime Global has experienced exceptional organic growth in recent years, including the 2020 launches of Prime Access, a Market Access consultancy, and IRIS, a high-level strategic consultancy, as well as acquiring a new agency, Cambridge, in May 2020. The company is delighted to rank on several business growth lists such as the Sunday Times Fast Track 100 in 2018, 2019, and 2020, and has been listed in the top ten of the Alantra Fast Pharma 50 in 2019, 2020, and 2021.
Find out more about Prime Omics: https://primeglobalpeople.com/prime-omics-part-of-the-prime-global-group/